Regcell raised $66 million, with Japanese government support included, to advance its regulatory T-cell (Treg) platform toward clinical development. The company’s approach is based on converting disease-driving immune cells into antigen-specific Tregs using an epigenetic reprogramming strategy tied to Nobel-linked immune tolerance research. The funding is aimed at translating the platform into clinical-grade assets and scaling development toward human studies. For the immune-oncology and autoimmune markets, the financing underscores investor interest in precision immunoregulation rather than generalized immunosuppression.